 |
|
Variables Influencing Penicillin Treatment Outcome in Streptococcal Tonsillopharyngitis
Michael E. Pichichero, MD;
William Hoeger, MD;
Steven M. Marsocci, MD;
A. Marie Lynd Murphy, MD;
Anne B. Francis, MD;
Vladimir Dragalin, PhD
Arch Pediatr Adolesc Med. 1999;153:565-570.
Objective To examine whether penicillin treatment success for group A  -hemolytic streptococcal tonsillopharyngitis is influenced by patient age, number of days ill prior to initiation of treatment, number of prior episodes, season, total dosage (milligrams per kilogram), and frequency of administration (2 vs 3 times daily).
Methods Four hundred seventy-eight children, adolescents, and young adults aged 2 to 21 years with acute symptoms compatible with the clinical diagnosis of group A -hemolytic streptococcal tonsillopharyngitis and a positive streptococcus rapid antigen detection test result were enrolled (intent-to-treat group). Patients were randomly assigned to receive penicillin V potassium, 250 mg 3 times daily (n=239) or 500 mg 2 times daily (n=239). Randomization was independent of patient body weight and treatment was for 10 days with both regimens. Follow-up examinations occurred, and cultures were obtained at 14 to 21 days after the initiation of antibiotic therapy; those with group A -hemolytic streptococcus isolated from a throat culture and who returned for follow-up were assessed for outcome (n=359).
Results Using a logistic regression analysis with a stepwise variable selection, we found the major variables associated with penicillin treatment success to be the number of days ill prior to initiation of treatment (P=.001; odds ratio, 1.55 [95% confidence interval, 1.2-2.1]) and the age of the child when infected (P=.004; odds ratio, 1.14 [95% confidence interval, 1.05-1.25]). The number of prior episodes within the preceding year, the season, the total daily penicillin dose (range, 8-76 mg/kg), and 2 vs 3 times daily dosing did not significantly alter treatment outcome.
Conclusion Treatment after 2 days of illness and of adolescent patients increases penicillin treatment success for group A -hemolytic streptococcal tonsillopharyngitis.
From the Departments of Microbiology/Immunology (Dr Pichichero) and Biostatistics (Dr Dragalin), University of Rochester, and the Elmwood Pediatric Group (Drs Pichichero, Hoeger, Marsocci, Murphy, and Francis), Rochester, NY.
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
The Importance of Bacteriologic Eradication in the Treatment of Group A Streptococcal Tonsillopharyngitis
Pichichero
CLIN PEDIATR 2007;46:3S-16S.
ABSTRACT
Explaining the Poor Bacteriologic Eradication Rate of Single-Dose Ceftriaxone in Group A Streptococcal Tonsillopharyngitis: A Reverse Engineering Solution Using Pharmacodynamic Modeling
Blumer et al.
Pediatrics 2005;116:927-932.
ABSTRACT
| FULL TEXT
How Do You Improve Compliance?
Winnick et al.
Pediatrics 2005;115:e718-e724.
ABSTRACT
| FULL TEXT
Meta-analysis of Cephalosporin Versus Penicillin Treatment of Group A Streptococcal Tonsillopharyngitis in Children
Casey and Pichichero
Pediatrics 2004;113:866-882.
ABSTRACT
| FULL TEXT
Biofilm Formation by Group A Streptococci: Is There a Relationship with Treatment Failure?
Conley et al.
J. Clin. Microbiol. 2003;41:4043-4048.
ABSTRACT
| FULL TEXT
Efficacy of Cephalexin Two vs. Three Times Daily vs. Cefadroxil Once Daily for Streptococcal Tonsillopharyngitis
Curtin et al.
CLIN PEDIATR 2003;42:519-526.
ABSTRACT
Efficacy of Penicillin vs. Amoxicillin in Children with Group A Beta Hemolytic Streptococcal Tonsillopharyngitis
Curtin-Wirt et al.
CLIN PEDIATR 2003;42:219-225.
ABSTRACT
Eradication of Group A Streptococci
Pichichero; et al.
Pediatrics 2000;106:380-381.
FULL TEXT
Variables Influencing Penicillin Treatment Outcome
Bergman et al.
Arch Pediatr Adolesc Med 2000;154:91-91.
FULL TEXT
Cost-effective Management of Sore Throat: It Depends on the Perspective
Pichichero
Arch Pediatr Adolesc Med 1999;153:672-674.
FULL TEXT
|
